
Michael E Weinblatt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/103206/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism, 1995, 38, 727-735.	6.7	2,531
2	A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate. New England Journal of Medicine, 1999, 340, 253-259.	27.0	2,044
3	Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis and Rheumatism, 2003, 48, 35-45.	6.7	1,612
4	The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis and Rheumatism, 1993, 36, 729-740.	6.7	1,388
5	Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis. New England Journal of Medicine, 1985, 312, 818-822.	27.0	833
6	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. New England Journal of Medicine, 2017, 376, 652-662.	27.0	643
7	Methotrexate for Rheumatoid Arthritis. Arthritis and Rheumatism, 1994, 37, 316-328.	6.7	594
8	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research, 2021, 73, 924-939.	3.4	466
9	An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis. New England Journal of Medicine, 2010, 363, 1303-1312.	27.0	369
10	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 1108-1123.	5.6	339
11	Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelveâ€week, randomized, placeboâ€controlled trial. Arthritis and Rheumatism, 2008, 58, 3309-3318.	6.7	313
12	Infections and anti-tumor necrosis factor ? therapy. Arthritis and Rheumatism, 2003, 48, 3013-3022.	6.7	285
13	Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis. A multicenter study with literature review. Arthritis and Rheumatism, 1997, 40, 1829-1837.	6.7	279
14	Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Annals of the Rheumatic Diseases, 2006, 66, 228-234.	0.9	261
15	Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Annals of the Rheumatic Diseases, 2014, 73, 86-94.	0.9	256
16	Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis and Rheumatism, 1999, 42, 1322-1328.	6.7	248
17	Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis and Rheumatism, 1988, 31, 167-175.	6.7	235
18	Long-Term Prospective Study of Methotrexate in the Treatment of Rheumatoid Arthritis. Arthritis and Rheumatism, 1992, 35, 129-137.	6.7	227

#	Article	IF	CITATIONS
19	Headâ€ŧoâ€head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis and Rheumatism, 2013, 65, 28-38.	6.7	225
20	Methotrexate in rheumatoid arthritis. a five-year prospective multicenter study. Arthritis and Rheumatism, 1994, 37, 1492-1498.	6.7	216
21	Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. Arthritis and Rheumatism, 1987, 30, 988-997.	6.7	207
22	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVIDâ€19 Pandemic: Version 3. Arthritis and Rheumatology, 2021, 73, e1-e12.	5.6	201
23	An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A threeâ€month randomized, placebo ontrolled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis and Rheumatism, 2011, 63, 337-345.	6.7	190
24	Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis and Rheumatism, 1993, 36, 329-335.	6.7	187
25	Etanercept in the treatment of adult patients with Still's disease. Arthritis and Rheumatism, 2002, 46, 1171-1176.	6.7	179
26	Efficacy and Safety of ABTâ€494, a Selective JAKâ€1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis and Rheumatology, 2016, 68, 2857-2866.	5.6	172
27	Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1445-1452.	0.9	149
28	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVIDâ€19 Pandemic: Version 1. Arthritis and Rheumatology, 2020, 72, 1241-1251.	5.6	142
29	Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept) Tj ETQq1 1 therapy. Annals of the Rheumatic Diseases, 2014, 73, 1616-1625.	0.784314 0.9	rgBT /Overlo 135
30	Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1042-1055.	5.6	135
31	Cyclosporin A Treatment of Refractory Rheumatoid Arthritis. Arthritis and Rheumatism, 1987, 30, 11-17.	6.7	134
32	Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Annals of the Rheumatic Diseases, 2016, 75, 709-714.	0.9	134
33	How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion. Arthritis and Rheumatism, 2002, 47, 215-218.	6.7	132
34	Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. Arthritis and Rheumatism, 1990, 33, 330-338.	6.7	126
35	A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1020-1030.	0.9	117
36	Methotrexate in rheumatoid arthritis: a quarter century of development. Transactions of the American Clinical and Climatological Association, 2013, 124, 16-25.	0.5	117

#	Article	IF	CITATIONS
37	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology, 2012, 51, 2204-2214.	1.9	115
38	Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program. Journal of Rheumatology, 2013, 40, 787-797.	2.0	112
39	A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 846-854.	2.0	108
40	Phase <scp>III</scp> Randomized Study of <scp>SB</scp> 5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderateâ€toâ€5evere Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 40-48.	5.6	104
41	Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 832-840.	5.6	103
42	The Association Between Reduction in Inflammation and Changes in Lipoprotein Levels and HDL Cholesterol Efflux Capacity in Rheumatoid Arthritis. Journal of the American Heart Association, 2015, 4, .	3.7	102
43	The effects of drug therapy on radiographic progression of rheumatoid arthritis. results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis and Rheumatism, 1993, 36, 613-619.	6.7	100
44	Acute and chronic suppression of leukotriene B4 synthesis EX vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis and Rheumatism, 1992, 35, 376-384.	6.7	99
45	Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled, Parallelâ€Group Study. Arthritis and Rheumatology, 2014, 66, 3255-3264.	5.6	96
46	Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Annals of the Rheumatic Diseases, 2013, 72, 381-389.	0.9	90
47	The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderateâ€toâ€Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Doubleâ€Blind, Placebo/Activeâ€Controlled, Doseâ€Ranging Study. Arthritis and Rheumatology, 2015, 67, 2591-2600.	5.6	86
48	Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis and Rheumatism, 1989, 32, 1592-1596.	6.7	85
49	Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Annals of the Rheumatic Diseases, 2017, 76, 1853-1861.	0.9	83
50	Functional Impact of a Spectrum of Interstitial Lung Abnormalities in Rheumatoid Arthritis. Chest, 2014, 146, 41-50.	0.8	78
51	Phase <scp>II</scp> Study of <scp>ABT</scp> â€122, a Tumor Necrosis Factor– and Interleukinâ€17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate. Arthritis and Rheumatology, 2018, 70, 1778-1789.	5.6	77
52	A Randomized Phase <scp>II</scp> b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 49-59.	5.6	76
53	The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. Rheumatology, 2015, 54, 2076-2084.	1.9	74
54	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nature Communications, 2016, 7, 12460.	12.8	73

#	Article	IF	CITATIONS
55	Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‣timulating Factor Receptor α Monoclonal Antibody. Arthritis and Rheumatology, 2018, 70, 679-689.	5.6	73
56	Serum 14-3-3η is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2014, 41, 2104-2113.	2.0	72
57	Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, doubleâ€blind, active drug–controlled study. Arthritis and Rheumatism, 2008, 58, 1921-1930.	6.7	71
58	Granulomatous lung disease occurring during etanercept treatment. Arthritis and Rheumatism, 2005, 53, 618-620.	6.7	70
59	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVIDâ€19 Pandemic: Version 2. Arthritis and Rheumatology, 2020, 72, e1-e12.	5.6	64
60	Inhibition of Leukotriene B ₄ synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis and Rheumatism, 1990, 33, 1149-1155.	6.7	63
61	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Annals of the Rheumatic Diseases, 2020, 79, 88-93.	0.9	63
62	Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care and Research, 2011, 63, 373-382.	3.4	58
63	Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. Seminars in Arthritis and Rheumatism, 2015, 45, 167-173.	3.4	58
64	Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Research and Therapy, 2008, 10, R95.	3.5	57
65	A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-α Antagonist. Journal of Rheumatology, 2014, 41, 2120-2128.	2.0	57
66	Tocilizumab as monotherapy or in combination with nonbiologic diseaseâ€modifying antirheumatic drugs: Twentyâ€four–week results of an openâ€label, clinical practice study. Arthritis Care and Research, 2013, 65, 362-371.	3.4	56
67	<scp>ABT</scp> â€122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukinâ€17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate. Arthritis and Rheumatology, 2018, 70, 1710-1720.	5.6	55
68	Synovial tissue response to treatment with campath-1h. Arthritis and Rheumatism, 1995, 38, 254-258.	6.7	50
69	Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis and Rheumatism, 2005, 53, 872-878.	6.7	49
70	Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry. Arthritis Care and Research, 2017, 69, 1920-1925.	3.4	49
71	Serious liver disease in a patient receiving methotrexate and leflunomide. Arthritis and Rheumatism, 2000, 43, 2609-2611.	6.7	46
72	Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients. ACR Open Rheumatology, 2020, 2, 357-361.	2.1	43

#	Article	IF	CITATIONS
73	Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial. Journal of Rheumatology, 2013, 40, 369-378.	2.0	42
74	Modular Analysis of Peripheral Blood Gene Expression in Rheumatoid Arthritis Captures Reproducible Gene Expression Changes in Tumor Necrosis Factor Responders. Arthritis and Rheumatology, 2015, 67, 344-351.	5.6	42
75	Clinical characteristics of RA patients with secondary SS and association with joint damage. Rheumatology, 2015, 54, 816-820.	1.9	41
76	Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. Arthritis Research and Therapy, 2021, 23, 1.	3.5	41
77	OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Annals of the Rheumatic Diseases, 2015, 74, 2123-2129.	0.9	39
78	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Annals of the Rheumatic Diseases, 2019, 78, 872-878.	0.9	36
79	Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. Journal of Rheumatology, 2006, 33, 659-64.	2.0	34
80	Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). Journal of Rheumatology, 2021, 48, 767-774.	2.0	33
81	A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis and Rheumatology, 2017, 69, 1937-1948.	5.6	32
82	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. Annals of the Rheumatic Diseases, 2015, 74, 1567-1570.	0.9	31
83	Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. Rheumatology, 2018, 57, 1972-1981.	1.9	30
84	Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1â€year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. Annals of the Rheumatic Diseases, 2014, 73, 2152-2159.	0.9	29
85	Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia. Rheumatology, 2016, 55, 640-648.	1.9	29
86	Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. Journal of Rheumatology, 2008, 35, 1737-44.	2.0	27
87	Clinical Consequences of Delayed Addition of Adalimumab to Methotrexate Therapy Over 5 Years in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 855-862.	2.0	25
88	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and CD39. Annals of the Rheumatic Diseases, 2019, 78, 1055-1061.	0.9	25
89	Patientâ€Reported Outcomes From a Two‥ear Headâ€toâ€Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 907-913.	3.4	24
90	Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. Arthritis and Rheumatology, 2017, 69, 720-727.	5.6	24

#	Article	IF	CITATIONS
91	Factors Associated with Radiographic Progression in Patients with Rheumatoid Arthritis Who Were Treated with Methotrexate. Journal of Rheumatology, 2011, 38, 242-246.	2.0	23
92	The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. Arthritis Research and Therapy, 2006, 8, R57.	3.5	22
93	Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Advances, 2021, 5, 3445-3456.	5.2	22
94	Rheumatoid factor detection by nephelometry. Arthritis and Rheumatism, 1980, 23, 777-779.	6.7	21
95	Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1419-1428.	5.6	21
96	Methotrexate: who would have predicted its importance in rheumatoid arthritis?. Arthritis Research and Therapy, 2018, 20, 103.	3.5	18
97	Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. BMC Rheumatology, 2019, 3, 3.	1.6	18
98	Rheumatoid arthritis-related lung disease detected on clinical chest computed tomography imaging: Prevalence, risk factors, and impact on mortality. Seminars in Arthritis and Rheumatism, 2020, 50, 1216-1225.	3.4	18
99	Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Research and Therapy, 2015, 17, 325.	3.5	16
100	Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. Rheumatology, 2019, 58, 874-883.	1.9	16
101	N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: A pilot study. Arthritis and Rheumatism, 1996, 39, 1021-1026.	6.7	15
102	Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids. Arthritis and Rheumatology, 2018, 70, 1331-1342.	5.6	15
103	Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). Rheumatology and Therapy, 2019, 6, 559-571.	2.3	15
104	Rheumatoid arthritis: more aggressive approach improves outlook Cleveland Clinic Journal of Medicine, 2004, 71, 409-413.	1.3	14
105	The Effect of Intravenous Golimumab on Health-related Quality of Life in Rheumatoid Arthritis: 24-week Results of the Phase III GO-FURTHER Trial. Journal of Rheumatology, 2014, 41, 1067-1076.	2.0	14
106	Screening for preclinical parenchymal lung disease in rheumatoid arthritis. Rheumatology, 2022, 61, 3234-3245.	1.9	14
107	Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Weekâ€112 Efficacy and Safety Results of the Openâ€Label Longâ€Term Extension of a Phase III, Doubleâ€Blind, Randomized, Placeboâ€Controlled Trial. Arthritis Care and Research, 2015, 67, 1627-1636.	3.4	13
108	Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. Arthritis Research and Therapy, 2015, 17, 343.	3.5	13

#	Article	IF	CITATIONS
109	An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. Arthritis Research and Therapy, 2015, 17, 83.	3.5	13
110	Impact of Changes in Inflammation on Estimated Ten‥ear Cardiovascular Risk in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1392-1398.	5.6	13
111	Fibromyalgia and the Prediction of Twoâ€Year Changes in Functional Status in Rheumatoid Arthritis Patients. Arthritis Care and Research, 2017, 69, 1871-1877.	3.4	12
112	Prevalence and predictors for sustained remission in rheumatoid arthritis. PLoS ONE, 2019, 14, e0214981.	2.5	12
113	Dataâ€Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. Arthritis Care and Research, 2021, 73, 471-480.	3.4	12
114	Treatment of rheumatoid arthritis. Arthritis and Rheumatism, 1989, 2, A23-A32.	6.7	11
115	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: TableÂ1. Annals of the Rheumatic Diseases, 2014, 73, 1755-1760.	0.9	11
116	Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry. Clinical Rheumatology, 2019, 38, 3401-3412.	2.2	11
117	Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Diseaseâ€Modifying Antirheumatic Drugs: Results From a Realâ€World Study. Arthritis Care and Research, 2020, 72, 176-183.	3.4	11
118	Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis. Clinical Rheumatology, 2021, 40, 1259-1271.	2.2	11
119	Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis. Rheumatology and Therapy, 2018, 5, 203-214.	2.3	10
120	The best of times, the worst of times: Rheumatology 2001. Arthritis and Rheumatism, 2002, 46, 567-573.	6.7	9
121	Case 13-2009. New England Journal of Medicine, 2009, 360, 1770-1779.	27.0	9
122	Inconsistent Treatment with Disease-modifying Antirheumatic Drugs: A Longitudinal Data Analysis. Journal of Rheumatology, 2014, 41, 2370-2378.	2.0	9
123	The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure) Tj ETQq1 1	0.78 243 14 r	gB⊅/Overlo⊂
124	Validity of the Nurses' health study physical activity questionnaire in estimating physical activity in adults with rheumatoid arthritis. BMC Musculoskeletal Disorders, 2017, 18, 234.	1.9	9
125	Association of Low Bone Mineral Density with Anti-Citrullinated Protein Antibody Positivity and Disease Activity in Established Rheumatoid Arthritis: Findings from a US Observational Cohort. Advances in Therapy, 2018, 35, 232-242.	2.9	9
126	Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLoS ONE, 2018, 13, e0205013.	2.5	9

#	Article	IF	CITATIONS
127	The Impact of Exercise, Lifestyle, and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study. ACR Open Rheumatology, 2019, 1, 620-626.	2.1	9
128	The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies. Journal of Rheumatology, 2020, 48, jrheum.200692.	2.0	9
129	Lack of a renal–protective effect of misoprostol in rheumatoid arthritis patients receiving cyclosporin a. results of a randomized, placebo–controlled trial. Arthritis and Rheumatism, 1994, 37, 1321-1325.	6.7	8
130	Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis. Clinical Pharmacology and Therapeutics, 1986, 39, 420-424.	4.7	7
131	Clinical patient registry recruitment and retention: a survey of patients in two chronic disease registries. BMC Medical Research Methodology, 2017, 17, 59.	3.1	7
132	Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate. Annals of the Rheumatic Diseases, 2018, 77, e4-e4.	0.9	7
133	Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach. ACR Open Rheumatology, 2019, 1, 552-559.	2.1	7
134	Rheumatoid arthritis quality measures and radiographic progression. Seminars in Arthritis and Rheumatism, 2014, 44, 9-13.	3.4	6
135	Treatment of Severe Multicentric Reticulohistiocytosis With Upadacitinib. JAMA Dermatology, 2021, 157, 735.	4.1	6
136	RAPID: rheumatoid arthritis. Journal of Family Practice, 2007, 56, S1-7; quiz S8.	0.2	6
137	The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease) Tj ETQq1 1 C).784314 i 2.2	gBJ /Overlo
138	Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept. Annals of the Rheumatic Diseases, 2019, 78, 1285-1286.	0.9	5
139	Incidence and Predictors of Dyspnea on Exertion in a Prospective Cohort of Patients With Rheumatoid Arthritis. ACR Open Rheumatology, 2019, 1, 4-15.	2.1	5
140	Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, and Medication Change. Journal of Rheumatology, 2020, 47, 333-340.	2.0	5
141	Perceptions and Challenges Experienced by African Physicians When Prescribing Methotrexate for Rheumatic Disease: An Exploratory Study. ACR Open Rheumatology, 2021, 3, 522-530.	2.1	4
142	Targeted therapies for psoriatic arthritis: an update for the dermatologist. Seminars in Cutaneous Medicine and Surgery, 2018, 37, 173-181.	1.6	4
143	The Role of Shared Epitope in Rheumatoid Arthritis Prognosis in Relation to Anti-Citrullinated Protein Antibody Positivity. Rheumatology and Therapy, 2022, 9, 637-647.	2.3	4
144	Chronic Monocytic Arthritis. Arthritis and Rheumatism, 1983, 26, 674-677.	6.7	3

#	Article	IF	CITATIONS
145	Evaluation of two interventions to reduce the ancillary costs of outpatient care for rheumatoid arthritis. Arthritis and Rheumatism, 1996, 39, 177-178.	6.7	3
146	Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration. RMD Open, 2016, 2, e000210.	3.8	3
147	Refractory Syndrome of Inappropriate Secretion of Antidiuretic Hormone in Systemic Lupus Erythematosus–associated Hypophysitis. Journal of Rheumatology, 2017, 44, 541-542.	2.0	3
148	FRI0171â€CLINICAL RESPONSES IN PATIENTS WITH INADEQUATE RESPONSE TO BDMARDS UPON TREATMENT WITH UPADACITINIB. , 2019, , .		3
149	Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. RMD Open, 2020, 6, e001096.	3.8	3
150	Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis. Rheumatology and Therapy, 2022, 9, 391-409.	2.3	3
151	Antimelanoma Differentiation-associated Gene 5 Dermatomyositis. Journal of Rheumatology, 2017, 44, 850-851.	2.0	2
152	Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement. Arthritis Research and Therapy, 2017, 19, 130.	3.5	2
153	Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis. Practical Laboratory Medicine, 2019, 16, e00122.	1.3	2
154	Rheumatoid Nodule Formation in the Kidney: A Diagnosis of Exclusion and a Rare Manifestation of Rheumatoid Arthritis Involving the Kidney. Kidney International Reports, 2019, 4, 745-748.	0.8	2
155	Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 188.	3.5	2
156	Methotrexate: The Foundation of Rheumatoid Arthritis Therapy. , 2009, , 307-314.		1
157	Editorial: The Vital Role of Randomized Controlled Trials in <i>Arthritis & Rheumatology</i> . Arthritis and Rheumatology, 2015, 67, 2555-2556.	5.6	1
158	Georgia Abortion Law and Our Commitment to Patients. Arthritis and Rheumatology, 2020, 72, 377-378.	5.6	1
159	86. Head-to-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in Rheumatoid Arthritis: Blinded Two-Year Results from the Ample Study. Rheumatology, 2014, 53, i88-i88.	1.9	0
160	221 Development of abatacept- and adalimumab-specific predictive models of response to therapy in rheumatoid arthritis using data from a head-to-head study. Rheumatology, 2018, 57, .	1.9	0
161	Association of Changes in Anticitrullinated Protein Antibody Levels With Resource Use and Disease Activity Measures in Rheumatoid Arthritis Patients aÂUS Observational Cohort. Clinical Therapeutics, 2019, 41, 1057-1065.e3.	2.5	0
162	AB0373â€A COMPARATIVE EFFECTIVENESS STUDY OF ABATACEPT AND TNFI AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS USING REAL-WORLD DATA. , 2019, , .		0

#	Article	IF	CITATIONS
163	SAT0072â€EVALUATION OF RHEUMATOID ARTHRITIS TREATMENTS AND JOINT OUTCOMES IN RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE. , 2019, , .		0
164	THU0065â€VALIDATION OF THE ADJUSTED MULTI-BIOMARKER DISEASE ACTIVITY SCORE FOR PREDICTING RIS OF RADIOGRAPHIC PROGRESSION FOR PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .	K	0
165	SAT0162â€A POOLED ANALYSIS OF 1-YEAR CLINICAL OUTCOMES AMONG 6-MONTH RESPONDERS AND NON-RESPONDERS FROM THREE RANDOMISED CONTROLLED STUDIES OF TNF INHIBITOR BIOSIMILARS IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
166	THU0102â€PATIENT DISEASE TRAJECTORIES IN BARICITINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE. , 2019, , .		0
167	Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis. Journal of Clinical Medicine, 2020, 9, 2017.	2.4	0
168	Dr. Kremer et al reply. Journal of Rheumatology, 2021, , jrheum.210992.	2.0	0
169	Serum Proteomics Reveals Distinct Subtypes Associated with Treatment Response in Idiopathic Multicentric Castleman Disease. Blood, 2018, 132, 3716-3716.	1.4	0
170	Questions and answers in 2008 about biologics in rheumatoid arthritis. Journal of Rheumatology, 2008, 35, 1878-81.	2.0	0